Beilin Le
Director/Board Member at Mirxes Holding Co., Ltd.
Profile
Beilin Le currently works at Mirxes Holding Co., Ltd., as Non-Executive Director from 2021.
Dr. Le received his doctorate degree in 2015 from National University of Singapore and undergraduate degree in 2011 from Fudan University.
Beilin Le active positions
Companies | Position | Start |
---|---|---|
Mirxes Holding Co., Ltd.
Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Director/Board Member | 2020-12-31 |
Training of Beilin Le
Fudan University | Undergraduate Degree |
National University of Singapore | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Mirxes Holding Co., Ltd.
Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Finance |
- Stock Market
- Insiders
- Beilin Le